AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21118743 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily armodafinil 200 mg doses
Number of subjects: 42
Study 21118743 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily modafinil 200 mg doses
Number of subjects: 42
Study 18256342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 72
Study 18256342 — intervention group
Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 72
Study 16496124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar tendon graft (PT)
Number of subjects: 100
Study 16496124 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring tendon graft (HT)
Number of subjects: 100
Study 16496124 — intervention group
Group type: EXPERIMENTAL
Intervention: Returned to sports
Number of subjects: 100
Study 16496124 — intervention group
Group type: COMPARATOR
Intervention: Did not return to sports
Number of subjects: 100
Study 16496124 — intervention group
Group type: COMPARATOR
Intervention: Ceased sport activities
Number of subjects: 100
Study 14687345 — intervention group
Group type: EXPERIMENTAL
Intervention: Group exercise (GE) intervention
Number of subjects: 551
Study 14687345 — intervention group
Group type: COMPARATOR
Intervention: Flexibility and relaxation (FR) classes or no group activity (Control)
Number of subjects: 551
Study 10847311 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Group Therapy (IGT)
Number of subjects: 45
Study 10847311 — intervention group
Group type: COMPARATOR
Intervention: No experimental treatment (control)
Number of subjects: 45
Study 8635429 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs) including carbamazepine (CBZ), phenytoin (PHT), phenobarbital (PB), valproate (VPA)
Number of subjects: 30
Study 8635429 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 30
Study 8635429 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 8635429 — intervention group
Group type: COMPARATOR
Intervention: Untreated seizure patients
Number of subjects: 30
Study 1406880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol alone
Number of subjects: 120
Study 3904437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam 200 mg per day
Number of subjects: 3243
Study 3904437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam dosages ranging from 200 to 600 mg per day
Number of subjects: 3243
Study 30790361 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus and Bifidobacterium animalis subsp lactis)
Number of subjects: 290
Study 30790361 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 290
Study 30790361 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 290
Study 30790361 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 290
Study 29183240 — intervention group
Group type: EXPERIMENTAL
Intervention: 6‐hr continuing education training
Number of subjects: 0
Study 29183240 — intervention group
Group type: COMPARATOR
Intervention: No e‐mail reminder
Number of subjects: 0
Study 29183240 — intervention group
Group type: COMPARATOR
Intervention: E‐mail reminder
Number of subjects: 0
Study 26670665 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg/day for 24 weeks)
Number of subjects: 40
Study 26670665 — intervention group
Group type: COMPARATOR
Intervention: Control (without hormone replacement therapy)
Number of subjects: 40
Study 24561001 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INFS)
Number of subjects: 69
Study 24561001 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 69
Study 24561001 — intervention group
Group type: COMPARATOR
Intervention: Both INFS and FPNS
Number of subjects: 69
Study 23107081 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel (3 mL placed 3 minutes prior to IUD insertion)
Number of subjects: 200
Study 23107081 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel (3 mL placed 3 minutes prior to IUD insertion)
Number of subjects: 200
Study 20573150 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention combining outreach visits, reminders, and peer reviews implemented by a team of an obstetrician and a midwife.
Number of subjects: 106
Study 20573150 — intervention group
Group type: COMPARATOR
Intervention: Control group with passive dissemination of the protocol.
Number of subjects: 106
Study 20573150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention units' management practices.
Number of subjects: 106
Study 17536049 — intervention group
Group type: EXPERIMENTAL
Intervention: Moving text (MT) therapy for two 4-week blocks
Number of subjects: 19
Study 17536049 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (spot the difference) for the first block, then crossed over to MT for the second block
Number of subjects: 19
Study 16270403 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha plus lamivudine (5 MU thrice per week + 100 mg daily)
Number of subjects: 50
Study 16270403 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine only (100 mg daily)
Number of subjects: 50
Study 16270403 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha plus lamivudine
Number of subjects: 50
Study 16270403 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine only
Number of subjects: 50
Study 12426861 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant extracts (e.g., Serenoa repens, Pygeum Africanum, pumpkin seeds)
Number of subjects: 0
Study 12426861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9973588 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational smoking cessation intervention
Number of subjects: 1064
Study 9973588 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1064
Study 8528973 — intervention group
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR) 0.5 mg/kg/day + L-folinic acid (L-FA) 10 mg/m2/day
Number of subjects: 14
Study 8528973 — intervention group
Group type: EXPERIMENTAL
Intervention: Floxuridine (FUDR) 0.525 mg/kg/day + L-folinic acid (L-FA) 10 mg/m2/day
Number of subjects: 14
Study 2301050 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics (cefoxitin)
Number of subjects: 2097
Study 2301050 — intervention group
Group type: EXPERIMENTAL
Intervention: Age over 25 years
Number of subjects: 2097
Study 2301050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative antibiotics for gangrenous or perforated appendix
Number of subjects: 2097
Study 2301050 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics for perforation
Number of subjects: 2097
Study 2301050 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient delay (time from onset of symptoms till admission)
Number of subjects: 2097
Study 76223 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group (25-50 mg hydrochlorothiazide and 50-100 mg triamterene daily, with half also receiving 250 mg to 2 g methyldopa daily)
Number of subjects: 119
Study 76223 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 119
Study 76223 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment group
Number of subjects: 119
Study 31682466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear appeal
Number of subjects: 315
Study 31682466 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal appeal
Number of subjects: 315
Study 31682466 — intervention group
Group type: COMPARATOR
Intervention: Social appeal
Number of subjects: 315
Study 31403986 — intervention group
Group type: EXPERIMENTAL
Intervention: Family obligation stress measure
Number of subjects: 539
Study 27914653 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy (target INR of 2.0 to 3.0)
Number of subjects: 370
Study 27914653 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 150mg daily
Number of subjects: 370
Study 25792206 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 24
Study 25792206 — intervention group
Group type: COMPARATOR
Intervention: Sham (SHAM)
Number of subjects: 24
Study 23327487 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol supplementation
Number of subjects: 75
Study 23327487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 21640348 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD+virgin olive oil (VOO)
Number of subjects: 551
Study 21640348 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (control)
Number of subjects: 551
Study 19490208 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-U BoNTA
Number of subjects: 363
Study 19490208 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-U BoNTA
Number of subjects: 363
Study 19490208 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 363
Study 17039398 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent prevention program
Number of subjects: 138
Study 17039398 — intervention group
Group type: EXPERIMENTAL
Intervention: Early identification and resolution of perceived barriers
Number of subjects: 138
Study 14971625 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 144
Study 14971625 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 144
Study 14971625 — intervention group
Group type: COMPARATOR
Intervention: Standard care plus a booklet
Number of subjects: 144
Study 11129364 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity home-based exercise
Number of subjects: 173
Study 11129364 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity home-based exercise
Number of subjects: 173
Study 11129364 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity class-based exercise
Number of subjects: 173
Study 11129364 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 or 1 major life event)
Number of subjects: 173
Study 9614998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterosorbent 'Silard P'
Number of subjects: 36
Study 9614998 — intervention group
Group type: COMPARATOR
Intervention: Generally-accepted complex therapy
Number of subjects: 36
Study 8467568 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 21
Study 8467568 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 21
Study 3897558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 15 mg/kg
Number of subjects: 294
Study 3897558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 20 mg/kg
Number of subjects: 294
Study 3897558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oltipraz 25 mg/kg
Number of subjects: 294
Study 3897558 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose
Number of subjects: 294
Study 3897558 — intervention group
Group type: COMPARATOR
Intervention: Divided dose taken 6 hours apart
Number of subjects: 294
Study 30781461 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 72
Study 30781461 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP injection)
Number of subjects: 72
Study 28432581 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intravitreal Bevacizumab
Number of subjects: 40
Study 28432581 — intervention group
Group type: COMPARATOR
Intervention: Deferred intravitreal Bevacizumab (after 3 months of observation)
Number of subjects: 40
Study 26690010 — intervention group
Group type: EXPERIMENTAL
Intervention: Single medium culture in a time-lapse incubator (TLI) without renewal on day 3
Number of subjects: 59
Study 26690010 — intervention group
Group type: COMPARATOR
Intervention: Two-step protocol
Number of subjects: 59
Study 26690010 — intervention group
Group type: COMPARATOR
Intervention: Mixed group (embryos selected from both protocols)
Number of subjects: 59
Study 24214232 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 0
Study 24214232 — intervention group
Group type: COMPARATOR
Intervention: Cinacalcet
Number of subjects: 0
Study 23210586 — intervention group
Group type: COMPARATOR
Intervention: Chest wall proximity constraint (1 cm)
Number of subjects: 0
Study 23210586 — intervention group
Group type: EXPERIMENTAL
Intervention: No chest wall proximity constraint
Number of subjects: 0
Study 19614962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz)
Number of subjects: 20
Study 19614962 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (placebo)
Number of subjects: 20
Study 18042825 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP)
Number of subjects: 60
Study 18042825 — intervention group
Group type: COMPARATOR
Intervention: Conventional etch and primer (AE)
Number of subjects: 60
Study 16104039 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant regimen (Day 1: APR 125 mg, OND 8 mg, DEX 12 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: APR 80 mg every day)
Number of subjects: 866
Study 16104039 — intervention group
Group type: COMPARATOR
Intervention: Control regimen (Day 1: OND 8 mg and DEX 20 mg before chemotherapy and OND 8 mg 8 hrs later; Days 2-3: OND 8 mg twice per day)
Number of subjects: 866
Study 16104039 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant regimen
Number of subjects: 866
Study 12115238 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 0.15 mg/kg/week (increased to 0.25 mg/kg/week, max 15 mg)
Number of subjects: 98
Study 12115238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 12115238 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 98
Study 10398353 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysthymic disorder group
Number of subjects: 40
Study 10398353 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed elderly group
Number of subjects: 40
Study 7573299 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride 0.5%
Number of subjects: 174
Study 7573299 — intervention group
Group type: COMPARATOR
Intervention: Placebo (apraclonidine's vehicle)
Number of subjects: 174
Study 1967534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (10 mg twice daily)
Number of subjects: 14
Study 1967534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 1967534 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 14
Study 7030632 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 77
Study 7030632 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 77
Study 31882409 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly exenatide therapy
Number of subjects: 14752
Study 31882409 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe hypoglycemic events (SHEs)
Number of subjects: 14752
Study 31882409 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfatal cardiovascular events (nonfatal MI, nonfatal stroke, hACS, hHF)
Number of subjects: 14752
Study 30777794 — intervention group
Group type: COMPARATOR
Intervention: TP (thalidomide 100 mg/d for ≤12 months/until disease progression; prednisolone 50 mg on alternate days indefinitely/until disease progression; n=100)
Number of subjects: 203
Study 30777794 — intervention group
Group type: EXPERIMENTAL
Intervention: VTP (subcutaneous bortezomib 1.3 mg/m2 every 2 weeks for 32 weeks, plus TP; n=103)
Number of subjects: 203
Study 28658357 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 37
Study 28658357 — intervention group
Group type: COMPARATOR
Intervention: Slow Maxillary Expansion (SME)
Number of subjects: 37
Study 25814432 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Glucose Tolerance (NGT) with Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated Impaired Fasting Glucose (IFG) with Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated Impaired Glucose Tolerance (IGT) with Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined IFG/IGT with Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: COMPARATOR
Intervention: Normal Glucose Tolerance (NGT) without Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: COMPARATOR
Intervention: Isolated Impaired Fasting Glucose (IFG) without Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: COMPARATOR
Intervention: Isolated Impaired Glucose Tolerance (IGT) without Hypertension
Number of subjects: 1489
Study 25814432 — intervention group
Group type: COMPARATOR
Intervention: Combined IFG/IGT without Hypertension
Number of subjects: 1489
Study 24051063 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/HCV educational intervention
Number of subjects: 54
Study 24051063 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV questionnaire
Number of subjects: 54
Study 24051063 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV questionnaire individual items
Number of subjects: 54
Study 24051063 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV questionnaire individual items
Number of subjects: 54
Study 24051063 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported likelihood of using a condom
Number of subjects: 54
Study 24051063 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported risk behaviors
Number of subjects: 54
Study 20336486 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 79
Study 20336486 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 79
Study 20812442 — intervention group
Group type: EXPERIMENTAL
Intervention: ACOG guidelines
Number of subjects: 81
Study 20812442 — intervention group
Group type: COMPARATOR
Intervention: EAST guidelines
Number of subjects: 81
Study 19275854 — intervention group
Group type: EXPERIMENTAL
Intervention: 21‐mm circular‐stapler
Number of subjects: 80
Study 19275854 — intervention group
Group type: EXPERIMENTAL
Intervention: 45‐mm linear‐stapler
Number of subjects: 80
Study 19275854 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 80
Study 16076335 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (10 mmHg)
Number of subjects: 53
Study 16076335 — intervention group
Group type: COMPARATOR
Intervention: High-pressure pneumoperitoneum (15 mmHg)
Number of subjects: 53
Study 11978956 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol sustained-release treatment
Number of subjects: 192
Study 11978956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 10421878 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAT and VAChT immunopositive neurons in the nucleus basalis of Meynert (nbM)
Number of subjects: 3
Study 10421878 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAT and VAChT immunopositive neurons
Number of subjects: 3
Study 8574276 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure device
Number of subjects: 96
Study 8574276 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupressure device for wrist
Number of subjects: 96
Study 2275356 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metyrapone tartrate
Number of subjects: 8
Study 2275356 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 8
Study 7314361 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex catheters
Number of subjects: 100
Study 7314361 — intervention group
Group type: COMPARATOR
Intervention: Teflon catheters
Number of subjects: 100
Study 30244181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (∼16 mmol nitrate per day)
Number of subjects: 15
Study 30244181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 27644437 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Attitudes Questionnaire (SAQ)
Number of subjects: 420
Study 23813562 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 46
Study 23813562 — intervention group
Group type: COMPARATOR
Intervention: Wait list-control
Number of subjects: 46
Study 22274169 — intervention group
Group type: EXPERIMENTAL
Intervention: GA plus TEA (TEA(perio) group)
Number of subjects: 64
Study 22274169 — intervention group
Group type: COMPARATOR
Intervention: GA alone (TEA(post) group)
Number of subjects: 64
Study 20357728 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stripping of cystic wall from the initial adhesion site (group A)
Number of subjects: 92
Study 20357728 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular excision of ovarian tissue around the initial adhesion site and then stripping (group B)
Number of subjects: 92
Study 20357728 — intervention group
Group type: COMPARATOR
Intervention: Both techniques (group A and group B)
Number of subjects: 92
Study 18558914 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated care plan including treatment for depression and anxiety disorders, containment strategy for somatisation, and service coordinator-assisted self-management.
Number of subjects: 124
Study 18558914 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Control group)
Number of subjects: 124
Study 16375964 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening gel containing hydrogen peroxide and sodium percarbonate formulation
Number of subjects: 12
Study 16375964 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 12
Study 12524411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% GTN ointment
Number of subjects: 200
Study 12524411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% GTN ointment
Number of subjects: 200
Study 12524411 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% GTN ointment
Number of subjects: 200
Study 12524411 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 200
Study 10645233 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolator 10 blood culture system
Number of subjects: 71
Study 10645233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pour plate method
Number of subjects: 71
Study 10645233 — intervention group
Group type: COMPARATOR
Intervention: Conventional broth based blood cultures
Number of subjects: 71